Literature DB >> 29452269

Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.

Suresh Senan1, Chad G Rusthoven2, Ben J Slotman3, Shankar Siva4.   

Abstract

This review highlights key publications and abstracts in the field of radiation oncology for lung cancer in 2017 and attempts to place these in the context of developments for the broader thoracic oncology community.
Copyright © 2018 International Association for the Study of Lung Cancer. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Immunotherapy; Non–small cell lung cancer; Oligometastatic disease; Radiotherapy; Stereotactic radiotherapy

Mesh：

Year:  2018        PMID： 29452269     DOI： 10.1016/j.jtho.2018.02.001

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


  5 in total

1.  Modified Glasgow Prognostic Score is predictive of prognosis for non-small cell lung cancer patients treated with stereotactic body radiation therapy: a retrospective study.

Authors:  Zhe Chen; Hotaka Nonaka; Hiroshi Onishi; Eiji Nakatani; Yoko Sato; Satoshi Funayama; Hiroaki Watanabe; Takafumi Komiyama; Kengo Kuriyama; Kan Marino; Shinichi Aoki; Masayuki Araya; Licht Tominaga; Ryo Saito; Yoshiyasu Maehata; Mitsuhiko Oguri; Masahide Saito
Journal:  J Radiat Res       Date:  2021-05-12       Impact factor: 2.724

Review 2.  SBRT combined with PD-1/PD-L1 inhibitors in NSCLC treatment: a focus on the mechanisms, advances, and future challenges.

Authors:  Yu Chen; Min Gao; Zhaoqin Huang; Jinming Yu; Xiangjiao Meng
Journal:  J Hematol Oncol       Date:  2020-07-28       Impact factor: 17.388

3.  Comparative effectiveness of concurrent chemoradiotherapy versus EGFR-tyrosine kinase inhibitors for the treatment of clinical stage IIIb lung adenocarcinoma patients with mutant EGFR.

Authors:  Te-Chun Hsia; Ji-An Liang; Chia-Chin Li; Chun-Ru Chien
Journal:  Thorac Cancer       Date:  2018-08-27       Impact factor: 3.500

4.  Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer.

Authors:  Min Wu; Jie Liu; Shihao Wu; Jingru Liu; Hui Wu; Jinming Yu; Xue Meng
Journal:  Front Immunol       Date:  2021-12-14       Impact factor: 7.561

5.  Analysis of key clinical features for achieving complete remission in stage III and IV non-small cell lung cancer patients.

Authors:  Takuya Aoki; Takeshi Akiba; Jun Nishiyama; Sakurako Tajiri; Naoki Hayama; Genki Takahashi; Jun Tanaka; Masako Sato; Hiroto Takiguchi; Hiromi Tomomatsu; Katsuyoshi Tomomatsu; Takahisa Takihara; Kyoko Niimi; Tsuyoshi Oguma; Mitsutomo Kohno; Ryota Masuda; Tetsuya Urano; Hitoshi Itoh; Hiroshi Kajiwara; Naoya Nakamura; Etsuo Kunieda; Mitsunori Matsumae; Masayuki Iwazaki; Koichiro Asano
Journal:  Respir Res       Date:  2019-11-21
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.